Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma.
Kaleigh E Lindholm, Peter A Forsberg, Mark D Ewalt
Author Information
- Kaleigh E Lindholm: Department of Pathology University of Colorado Anschutz Medical Campus Aurora Colorado USA. ORCID
- Peter A Forsberg: Department of Medicine Division of Hematology, University of Colorado Anschutz Medical Campus Aurora Colorado USA.
- Mark D Ewalt: Department of Pathology University of Colorado Anschutz Medical Campus Aurora Colorado USA.
No abstract text available.
- Future Oncol. 2014 May;10(6):957-67
[PMID: 24941982]
- EJHaem. 2021 Jun 20;2(3):565-568
[PMID: 35844727]
- N Engl J Med. 2012 Aug 30;367(9):826-33
[PMID: 22931316]
- Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):176-181
[PMID: 33358575]
- Am J Clin Pathol. 2003 Aug;120(2):246-53
[PMID: 12931555]
- Br J Haematol. 2017 Nov;179(3):439-448
[PMID: 28770576]
- Blood. 2014 Mar 13;123(11):1637-46
[PMID: 24366360]
- Leuk Lymphoma. 2018 May;59(5):1256-1259
[PMID: 28849690]
- J Blood Med. 2019 Aug 27;10:291-300
[PMID: 31695539]
- Blood. 2011 Jun 9;117(23):6287-96
[PMID: 21422473]
- J Oncol Pharm Pract. 2016 Feb;22(1):92-104
[PMID: 25425007]
